That's a wrap on #CGAIGC26! 🎉
Our 30th Annual Meeting in Denver was officially our most highly attended meeting to date, bringing together 530+ participants from 15 countries! 🌎
A huge THANK YOU to our attendees, speakers, presenters, committees, council members, sponsors, ng this milestone edition such a success!
🏖️ See you next year in Long Beach, California, for #CGAICC27!
Our 30th Annual Meeting in Denver was officially our most highly attended meeting to date, bringing together 530+ participants from 15 countries! 🌎
A huge THANK YOU to our attendees, speakers, presenters, committees, council members, sponsors, ng this milestone edition such a success!
🏖️ See you next year in Long Beach, California, for #CGAICC27!
0
0
3
71
Great to see @josepereag present at #CGAIGC26 & share the important #eoCRC work done by him & his group!
Dr. @josepereag, EOCRC Global Research Collaborative Advisor discussed Genetic Drivers Of Immunometabolism Influence Risk And Survival In Early- Onset Colorectal Cancer. Thanks to Dr. Perea for supporting patients globally and all his work with Fight CRC over the years!! #CGAIGC26 @CGAIGC
1
1
5
288
🎥 Does AI-assisted colonoscopy improve lesion detection in patients with #LynchSsyndrome?
At #CGAIGC26, @RHuneburg from University Hospital Bonn, Germany, shares findings from the CADLY-2 trial, published in The Lancet Gastroenterology & Hepatology
Watch this short video 👇 to hd their implications for Lynch syndrome surveillance.
#hereditarygicancer
At #CGAIGC26, @RHuneburg from University Hospital Bonn, Germany, shares findings from the CADLY-2 trial, published in The Lancet Gastroenterology & Hepatology
Watch this short video 👇 to hd their implications for Lynch syndrome surveillance.
#hereditarygicancer
1
3
4
247
📣We're excited to kick off #PancreaticCancerAwarenessMonth & sharing exciting advances in pancreatic cancer treatment!
At #CGAIGC26, Dr. Lindsay Davis, a medical oncologist from the @CUCancerCenter highlights emerging treatment options, including PARP inhibitors, immunew KRAS-targeted therapies.
With KRAS mutations found in approximately 93% of pancreatic cancers, these developments offer new hope for more personalized treatment approaches & improved patient outcomes.
📽️Watch this short sound bite 👇 to hear Dr. Davis share the latest developments & what they could mean for patients!
At #CGAIGC26, Dr. Lindsay Davis, a medical oncologist from the @CUCancerCenter highlights emerging treatment options, including PARP inhibitors, immunew KRAS-targeted therapies.
With KRAS mutations found in approximately 93% of pancreatic cancers, these developments offer new hope for more personalized treatment approaches & improved patient outcomes.
📽️Watch this short sound bite 👇 to hear Dr. Davis share the latest developments & what they could mean for patients!
0
2
4
132
CGA-IGC retweeted
ASCO member and JCO PO co-author Dr. Bryson Katona of @PennMedicine explains the data from “Pancreatic Imaging Findings in BRCA1/BRCA2/ATM/PALB2 Carriers”.
Learn more: bit.ly/48hxanf
Learn more: bit.ly/48hxanf
0
2
4
200
CGA-IGC retweeted
‼️ #CGAIGC26 simultaneous publication by Katona, et al.
Longitudinal Pancreatic Imaging Findings in BRCA1, BRCA2, ATM, and PALB2 Heterozygotes Undergoing Pancreatic Cancer Surveillance: A Prospective PRECEDE Consortium Study
Read the full publication. bit.ly/4Bnb007
Longitudinal Pancreatic Imaging Findings in BRCA1, BRCA2, ATM, and PALB2 Heterozygotes Undergoing Pancreatic Cancer Surveillance: A Prospective PRECEDE Consortium Study
Read the full publication. bit.ly/4Bnb007
0
4
4
260
🔛 NOW: Presidential Plenary II Session at #CGAIGC26, where Samantha Kasselman presents her abstract “Pancreatic Imaging Findings of PRECEDE Consortium Participants with Pathogenic Germline Variants in Breast Cancer Susceptibility Genes (ATM, BRCA1, BRCA2, PALB2),” which was d in the Journal of Precision Oncology (@JCOPO_ASCO).
0
0
4
185
🎥 Missed the Randall Burt Lecture at #CGAIGC26 or couldn't join us in Denver?
🙏to our Communications Committee member Benjamin Lerner, MD who caught up with James Ford, MD following his Randall Burt Lecture, “A Pre-Cancer Atlas for Hereditary Colorectal Cancer: Using FAP as a is insightful interview, Dr. Ford shares insights into how familial adenomatous polyposis (FAP) can serve as a model for understanding the earliest stages of colorectal cancer development and the potential implications for future cancer prevention strategies.
🎧 Take a few minutes to listen to this fascinating conversation and hear directly from Dr. Ford!
#HereditaryGICancer #CancerResearch
@MSpringerGC @EdEsplin @asaf_maoz @HHampel1 @AparajitaSingh0
🙏to our Communications Committee member Benjamin Lerner, MD who caught up with James Ford, MD following his Randall Burt Lecture, “A Pre-Cancer Atlas for Hereditary Colorectal Cancer: Using FAP as a is insightful interview, Dr. Ford shares insights into how familial adenomatous polyposis (FAP) can serve as a model for understanding the earliest stages of colorectal cancer development and the potential implications for future cancer prevention strategies.
🎧 Take a few minutes to listen to this fascinating conversation and hear directly from Dr. Ford!
#HereditaryGICancer #CancerResearch
@MSpringerGC @EdEsplin @asaf_maoz @HHampel1 @AparajitaSingh0
0
1
5
193
#CGAIGC26 provided the perfect opportunity to celebrate an important achievement in person: Lynch syndrome finally has its own dedicated ICD-10 code!
To mark this milestone, we hosted a special "HOW WE DO IT" session: PETITIONING FOR AND OBTAINING AN ICD-10 CODE FOR LYNCH rea Dwyer, MPH, and Peter Stanich, MD, 2 key collaborators in this effort, who shared the journey, challenges, & collaborative work that made this achievement possible.
Many🙏 to @FightCRC for garnering broad support from numerous organizations & individuals to make all of this possible!
🎥 Thanks to our past Communications Committee Chair @MSpringerGC for catching up with Andrea (Andi) Dwyer and Peter Stanich following the session to capture a quick sound bite!
#HereditaryGICancer
To mark this milestone, we hosted a special "HOW WE DO IT" session: PETITIONING FOR AND OBTAINING AN ICD-10 CODE FOR LYNCH rea Dwyer, MPH, and Peter Stanich, MD, 2 key collaborators in this effort, who shared the journey, challenges, & collaborative work that made this achievement possible.
Many🙏 to @FightCRC for garnering broad support from numerous organizations & individuals to make all of this possible!
🎥 Thanks to our past Communications Committee Chair @MSpringerGC for catching up with Andrea (Andi) Dwyer and Peter Stanich following the session to capture a quick sound bite!
#HereditaryGICancer
0
0
0
124
Melyssa Aronson takes the stage in the first Presidential Plenary session at #CGAIGC26 to present her abstract "Assessment of the 2022 Diagnostic Criteria for Constitutional Mismatch Repair Deficiency Syndrome (CMMRD) and Diagnoses of Individuals Referred to the International ortium (IRRDC)," which is simultaneously published in the Journal of Precision Oncology (@JCOPO_ASCO). 👏
1
2
6
285
CGA-IGC retweeted
‼️ #CGAIGC26 simultaneous publication by Aronson, et al.
Assessment of the 2022 Constitutional Mismatch Repair Deficiency Syndrome (CMMRD) Diagnostic Criteria Using the International Replication Repair Deficiency Consortium (IRRDC)
Read the full publication. bit.ly/4yHmWaC
Assessment of the 2022 Constitutional Mismatch Repair Deficiency Syndrome (CMMRD) Diagnostic Criteria Using the International Replication Repair Deficiency Consortium (IRRDC)
Read the full publication. bit.ly/4yHmWaC
0
3
1
227
Congratulations to Kristin Kohler on the presentation of her abstract in the first Presidential Plenary session at #CGAIGC26, as well as its simultaneous publication in the Journal of Precision Oncology! @JCOPO_ASCO
Read the abstract here: bit.ly/4BmjFAb
Read the abstract here: bit.ly/4BmjFAb
0
1
4
144
CGA-IGC retweeted
‼️ #CGAIGC26 simultaneous publication by Kohler, et al.
Redefining the EPCAM Phenotype: Deletion Architecture Determines Lynch Syndrome Cancer Risk
Read the full publication. bit.ly/4BmjFAb
Redefining the EPCAM Phenotype: Deletion Architecture Determines Lynch Syndrome Cancer Risk
Read the full publication. bit.ly/4BmjFAb
0
6
6
222
